Compare Amphastar Pharmaceuticals Inc (AMPH) vs Baker Hughes Co (BKR) Price & Performance

AMPH trades at $18.72, down 1.58% with bearish technical signals despite oversold RSI readings. The company reported mixed Q1 2026 results with EPS of $0.42 missing estimates of $0.70, continuing a trend of recent earnings disappointments. Valuation metrics appear reasonable with P/E of 11.29 and P/B of 1.07, while profitability remains solid with 47.34% gross margins. Recent news includes a Zacks Strong Sell rating and ongoing securities law investigation.

The stock faces near-term headwinds from earnings misses and negative analyst sentiment, though current valuations provide some downside protection. Upside potential exists if the company can execute its strategic pivot to proprietary drugs and biosimilars while managing BAQSIMI discount pressures. Key risks include ongoing legal scrutiny and competitive pressures in the generic drug market.

Baker Hughes (BKR) trades at $57.56, up 0.63% with a bearish technical signal despite recent earnings beats. The company shows strong fundamentals with P/E of 18.39, ROE of 17.14%, and consistent revenue growth from $21.2B in 2022 to $27.7B in 2025. Recent contract wins with Cheniere and Kodiak Gas Services highlight expansion in LNG and power infrastructure, supporting long-term growth prospects.

BKR presents a compelling investment case with analyst consensus price target of $73.45 (27% upside) and 66.7% buy ratings. Key opportunities include LNG infrastructure expansion and energy transition projects, while risks involve oil price volatility and execution of the $13.6B Chart Industries acquisition. The stock's current valuation appears reasonable given earnings growth trajectory.